Monoclonal Antibodies Market
Monoclonal Antibodies Market Size, Share & Trends Analysis Report by Source (Murine, Chimeric, Humanized, Human), by Indication (Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases), by End User (Hospitals, Research Institutes, Others), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)
|Forecast Years for Monoclonal Antibodies Market:||2022 - 2028|
|Historical Years for Monoclonal Antibodies Market:||2016 - 2021|
|Revenue 2021 for Monoclonal Antibodies Market:||USD 105.2 Billion|
|Revenue 2028 for Monoclonal Antibodies:||USD 155.2 Billion|
|Revenue CAGR (2022 - 2028) for Monoclonal Antibodies Market :||6.7%|
|Fastest Growing Region (2022 - 2028) for Monoclonal Antibodies Market:||Asia Pacific|
|Largest Region (2021) for Monoclonal Antibodies Market:||North America|
Global Monoclonal Antibodies Market:
Monoclonal Antibodies Market - By Source, Indication, End User, and Region.
The Global Monoclonal Antibodies Market is valued at USD 105.2 Billion in the year 2021 and is anticipated to reach a value of USD 155.2 Billion by the year 2028. The Global Market is forecasted to grow to exhibit a Compound Annual Growth Rate (CAGR) of 6.7% over the forecast period.
Monoclonal Antibodies are used widely in immunotherapy where they attach mono to specific proteins and cells. They are replicas of identical immune cells and are derived from parental cells. They bond to antigens as they have a monovalent affinity while administered. Increasing focus on healthcare is anticipated to bolster demand for Monoclonal Antibodies across the forecast period. Increasing investments in genomic research and development are projected to further bolster Monoclonal Antibodies Market growth through 2028.
Rising incidences of cancer, high demand for biologics, rising use of next-generation sequencing, and increasing investment in genetic engineering technologies are projected to be major factors that drive the Monoclonal Antibodies Market potential over the coming years. However, lack of awareness and absence of developed healthcare infrastructure is predicted to hinder the overall Monoclonal Antibodies Market growth over the forecast period. The growth of the Monoclonal Antibodies Market in developing economies is expected to be slower than in developed countries. Supportive government initiatives and favorable reimbursement policies are projected to bolster Monoclonal Antibodies Market potential.
The Monoclonal Antibodies Market is segmented based on Source, Indication, and End User and Region. Based on the End-User the market is segmented into Hospitals, Research Institutes, and Others. Based on the Source, the market is segmented as Murine, Chimeric, Humanized, and Human. Based on Indication, the market is segmented as Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, and Others.
Based on the End-User:
Based on End User segment, the market is segmented as Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, and Others. The Cancer sub-segment accounts for a major market share owing to the increasing prevalence of cancer across the world. Increasing investments in cancer treatment development are expected to bolster Monoclonal Antibodies demand on a global scale. Rising investments in Research and Development (R&D) of novel drugs is also expected to boost Monoclonal Antibodies demand.
Based on Source:
Based on the Source, the market is sub segmented into Murine, Chimeric, Humanized, and Human. The Human sub-segment is anticipated account for a dominant market share over the forecast period. Integration of advanced technologies and rising demand for Human Monoclonal Antibodies generation are prominent factors that drive the growth in the overall Monoclonal Antibodies Market across the world. Increasing demand for novel diagnostic and treatment procedures, rising prevalence of chronic diseases, and technological advancements in genomics are other factors that bolster growth in the overall Monoclonal Antibodies Market.
North America Accounts for a Dominant Market Share
The market for Monoclonal Antibodies in North America is projected to account for a significant market share owing to high investments in healthcare infrastructure. The increasing prevalence of cancer in this region is projected to boost demand for Monoclonal Antibodies through 2028. The presence of developed healthcare infrastructure and increasing investments in research and development of novel treatment and treatment drugs are projected to further boost Monoclonal Antibodies Market potential over the coming years. The Monoclonal Antibodies Market in North America accounted for a market share of 37.9% in 2021 and held a net worth of USD 39.8 billion in the same year. The Asia Pacific is projected to witness the fastest increase in demand for Monoclonal Antibodies as the incidence of cancer increases in the region. Supportive government initiatives are also expected to propel Monoclonal Antibodies Market potential through 2028.
The key players in the Global Monoclonal Antibodies Market include- Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer and others.
Segmentation of the Global Monoclonal Antibodies Market:
Regions & Countries Covered
Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST
analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market
attractiveness analysis by segments and North America, company market share analysis, and COVID-19
Frequently Asked Questions
the global demand for Monoclonal Antibodies
in terms of revenue?
The global Monoclonal Antibodies valued at USD 105.2 Billion in 2020 and is expected to reach USD 155.2 Billion in 2028 growing at a CAGR of 6.7%
are the prominent players
in the market?
The prominent players in the market are Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer.
At what CAGR is the market projected to grow within the forecast period?
The market is project to grow at a CAGR of 6.7% between 2021 and 2028.
the driving factors
fueling the growth of the market.
The driving factors of the Monoclonal Antibodies include
- Rise in prevalence of various cancer types
region accounted for the
largest share in the market?
North America was the leading regional segment of the Monoclonal Antibodies in 2020.